Incozen Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 10-07-2024
- Paid Up Capital ₹ 2.00 Cr
as on 10-07-2024
- Company Age 16 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 2.49 Cr
as on 10-07-2024
- Revenue 3.96%
(FY 2022)
- Profit -41.34%
(FY 2022)
- Ebitda -12.66%
(FY 2022)
- Net Worth 10.67%
(FY 2022)
- Total Assets 52.08%
(FY 2022)
About Incozen Therapeutics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 2.00 Cr.
The company has closed loans amounting to ₹2.49 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Pranav Amin, Shaunak Amin, Satya Vakkalanka, and One other member serve as directors at the Company.
- CIN/LLPIN
U24239TG2008PTC059967
- Company No.
059967
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Jul 2008
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Incozen Therapeutics Private Limited offer?
Incozen Therapeutics Private Limited offers a wide range of products and services, including Pharma & Bioanalytical Services, Pharmaceutical Services.
Who are the key members and board of directors at Incozen Therapeutics?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pranav Amin  | Director | 25-Nov-2008 | Current |
| Shaunak Amin | Director | 25-Nov-2008 | Current |
| Satya Vakkalanka | Director | 30-Aug-2008 | Current |
| Thappali Manikandan | Director | 26-Aug-2022 | Current |
Financial Performance and Corporate Structure Insights of Incozen Therapeutics.
Incozen Therapeutics Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 3.96% increase. The company also saw a substantial fall in profitability, with a 41.34% decrease in profit. The company's net worth Soared by an impressive increase of 10.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Incozen Therapeutics?
In 2022, Incozen Therapeutics had a promoter holding of 100.00%. The company had 2 Associate Companies. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Alembic Pharmaceuticals LimitedActive 14 years 6 monthsPranav Amin and Shaunak Amin are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 Aug 2011 | ₹2.49 Cr | Satisfied |
How Many Employees Work at Incozen Therapeutics?
Incozen Therapeutics has a workforce of 26 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Incozen Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Incozen Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
